Literature DB >> 9266835

The competitive binding of STAT3 and NF-kappaB on an overlapping DNA binding site.

Z Zhang1, G M Fuller.   

Abstract

Interleukin-1 (IL-1) and interleukin-6 (IL-6), two early-response cytokines expressed during an acute inflammatory reaction, regulate the expression of several acute phase proteins (APP) in the liver. IL-1 relays its signal to specific genes via NF-kappaB, whereas IL-6 sends its signal to the nucleus via STAT1alpha and STAT3. Interestingly, overlapping binding sites for STAT3 and NF-kappaB can be found on promoters of several APP genes. We show here that both STAT3 and NF-kappaB are active during inflammation and are capable of binding to a STAT3/NF-kappaB overlapping DNA motif derived from the alpha2-macroglobulin gene promoter. In vitro binding assays demonstrated that NF-kappaB competes with STAT3 binding on this probe. Our results suggest that these transcription factors regulate each others' function through competition for overlapping DNA binding sites.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266835     DOI: 10.1006/bbrc.1997.7082

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Cross-talk between interleukin 1beta (IL-1beta) and IL-6 signalling pathways: IL-1beta selectively inhibits IL-6-activated signal transducer and activator of transcription factor 1 (STAT1) by a proteasome-dependent mechanism.

Authors:  X Shen; Z Tian; M J Holtzman; B Gao
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

2.  STAT3/NF-κB interactions determine the level of haptoglobin expression in male rats exposed to dietary restriction and/or acute phase stimuli.

Authors:  Aleksandra Uskoković; Svetlana Dinić; Mirjana Mihailović; Nevena Grdović; Jelena Arambašić; Melita Vidaković; Desanka Bogojević; Svetlana Ivanović-Matić; Vesna Martinović; Miodrag Petrović; Goran Poznanović; Ilijana Grigorov
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

Review 3.  STAT3 and cardiac remodeling.

Authors:  Arash Haghikia; Britta Stapel; Melanie Hoch; Denise Hilfiker-Kleiner
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

Review 4.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

5.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB.

Authors:  Jinbo Yang; Xudong Liao; Mukesh K Agarwal; Laura Barnes; Philip E Auron; George R Stark
Journal:  Genes Dev       Date:  2007-05-17       Impact factor: 11.361

Review 6.  Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?.

Authors:  Bharat B Aggarwal; Ajaikumar B Kunnumakkara; Kuzhuvelil B Harikumar; Shan R Gupta; Sheeja T Tharakan; Cemile Koca; Sanjit Dey; Bokyung Sung
Journal:  Ann N Y Acad Sci       Date:  2009-08       Impact factor: 5.691

7.  Heme mediated STAT3 activation in severe malaria.

Authors:  Mingli Liu; Audu S Amodu; Sidney Pitts; John Patrickson; Jacqueline M Hibbert; Monica Battle; Solomon F Ofori-Acquah; Jonathan K Stiles
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

8.  Puerarin Alleviates UUO-Induced Inflammation and Fibrosis by Regulating the NF-κB P65/STAT3 and TGFβ1/Smads Signaling Pathways.

Authors:  Jingyu Wang; Shuke Ge; Yaqing Wang; Yi Liu; Lihua Qiu; Junying Li; Xin Huang; Li Sun
Journal:  Drug Des Devel Ther       Date:  2021-08-24       Impact factor: 4.162

9.  Interval-Based Secretomics Unravels Acute-Phase Response in Hepatocyte Model Systems.

Authors:  Sascha Knecht; H Christian Eberl; Marcus Bantscheff
Journal:  Mol Cell Proteomics       Date:  2022-05-05       Impact factor: 7.381

Review 10.  NF-κB, Mesenchymal Differentiation and Glioblastoma.

Authors:  Bakhtiar Yamini
Journal:  Cells       Date:  2018-08-31       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.